Hirotaka Ito
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
Journal: Nature
Published: February 21, 2023
Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models.
Journal: Molecular therapy oncolytics
Published: January 14, 2023
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.
Journal: Nature medicine
Published: January 16, 2022
Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation.
Journal: Molecular therapy oncolytics
Published: February 05, 2021
Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis.
Journal: Molecular therapy oncolytics
Published: January 18, 2021
Redesigned reporter gene for improved proton exchange-based molecular MRI contrast.
Journal: Scientific reports
Published: April 24, 2020
Quantitative imaging of apoptosis following oncolytic virotherapy by magnetic resonance fingerprinting aided by deep learning.
Journal: Nature biomedical engineering
Published: March 14, 2020
Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 05, 2020
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Journal: Molecular cell
Published: September 07, 2019
Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Journal: Scientific reports
Published: September 04, 2019
Last Updated: 09/26/2026